Sign in Subscribe

Latest

Short takeaways from the 2026 AAIC.

Short takeaways from the 2026 AAIC.

The 2026 Alzheimer's Association International Conference (AAIC 2026) took place in London, July 12-15 and gathered 13,000 attendees from 111 countries. 7,900 abstracts and presentations were disclosed. New treatments There was little novel information on new anti-amyloid efficacy data and more about defining next steps for

Alzheimer's disease: 19th CTAD announcement

Mark the date and location on your calendar. 19th Clinical Trials on Alzheimer's Disease Conference November 16-19, 2026 Boston, MA (USA) We're excited to announce that the preliminary program for the upcoming Clinical Trials on Alzheimer's Disease (CTAD) Conference 2026 is now available! This

Recent advances in Alzheimer’s disease research

Recent advances in Alzheimer’s disease research

Alzheimer’s disease is a complex neurodegenerative disorder that develops over several decades before clear clinical signs become visible. For many years, both basic and clinical research focused mainly on neuronal integrity and on the amyloid-beta hypothesis, which proposed that the disease could be treated by reducing plaque accumulation in

Un an avant l’élection présidentielle en France

Un an avant l’élection présidentielle en France

À travers l’Europe, les mouvements d’extrême droite attirent bien davantage l’attention que les forces démocratiques, et nous verrons probablement davantage de dirigeants démocratiquement élus adopter des comportements de plus en plus autoritaires. Comme beaucoup d’autres, j’essaie de comprendre pourquoi cette dynamique a pris autant d’

An update on recent deals

An update on recent deals

In our first two reports of the year, we noted that most biotechnology CEOs were concerned that, after a difficult and "morose" 2025, their companies faced an uncertain future. At the same time, investors had already identified a shift toward higher-value transactions and expected M&A activity

Réflexion d'un 1er Mai

Réflexion d'un 1er Mai

Fête du travail ou faites du travail ? La complexité et la fragmentation du monde contemporain, couplées aux instabilités politiques, géopolitiques, économiques et sociologiques, ont bouleversé les repères de nombreux managers et dirigeants d'entreprise. Face à ce chaos, il est tentant d’imaginer ou de croire qu'une

The top 20 pharma companies by 2025 revenue in US $

The top 20 pharma companies by 2025 revenue in US $

Each year, Fierce Pharma releases a series of comprehensive reports detailing the overall performance of the Biopharmaceutical industry. This particular report focuses on the leading 20 pharmaceutical companies ranked by their 2025 revenues, reported in US dollars. Notably, the composition of the top 20 companies remained unchanged compared to the

Top European & French Biotech Companies: Q1 2026

Top European & French Biotech Companies: Q1 2026

The European biotechnology sector continues to experience a subdued atmosphere, echoing the overall morosity that dominated most of 2025. As the first quarter of 2026 unfolds, the anticipated resurgence in deal activity has yet to materialise, with no European biotechnology company involved in a major transaction in this first period

The top 10 pharma R&D budgets of 2025

The top 10 pharma R&D budgets of 2025

According to Fierce Biotech Week, published on March 30, 2026 Top 10 pharma R&D budgets in 2025 Preamble. The top ten pharmaceutical companies with the largest research and development (R&D) budgets in 2025 remain unchanged from the previous year, with only minor shifts in their rankings.

When researchers discover a new mechanism of action for Alzheimer’s disease in a Traditional Chinese Medicine drug.

When researchers discover a new mechanism of action for Alzheimer’s disease in a Traditional Chinese Medicine drug.

For centuries, TCM has emphasised the strong link between the gut and the brain.

Japan approves two world's first iPS cell therapies

Japan approves two world's first iPS cell therapies

On the 6th of March, 2026, the Japan’s Ministry of Health, Labour and Welfare (MHLV) has granted conditional and time-limited approval to two first-of -a- kind regenerative medicines based on human induced pluripotent stem cells (iPSC). Recent Approvals The first one to Sumitomo Pharma for Amchepry, an allogenic iPS

Les entreprises européennes à la traîne

Les entreprises européennes à la traîne

Dans le top 50 des entreprises à la plus forte valorisation boursière, 34 sont américaines et seulement 6 sont européennes

The Rise of Chinese Biotechnology

The Rise of Chinese Biotechnology

According to Jefferies, one third of all biopharmaceutical licensing spend in 2025 was directed towards drugs originating from China

Biotechnology Sector Outlook and Recent Developments

Biotechnology Sector Outlook and Recent Developments

In every recent gathering of biotechnology executives, investors and business analysts, the prevailing sentiment has been one of increasing optimism as we move into 2026. Feedback from the J.P. Morgan ConferenceThe 44th Annual J.P. Morgan Healthcare Conference took place from January 12-15, 2026, in San Francisco. Although we